Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders

开发 SBI-553(一种 NTR1 变构调节剂),用于治疗物质使用障碍

基本信息

项目摘要

PROJECT SUMMARY Opioid use disorder (OUD) is a major public health crisis in the United States, with >50,000 overdose deaths in 2017 alone. Addiction to opioids is intimately related to the physiology of the brain’s dopamine-based rewarding system. The neurotensin 1 receptor (NTR1) is found among dopamine pre and post-synaptic neurons in the central nervous system, and acts as a modulator of dopaminergic systems. Even though substantial evidence points towards NTR1 as a molecular target for treating addiction disorders, few non- peptide brain penetrant neurotensin modulators have been identified, and orthosteric NTR1 ligands display side effects including hypotension and hypothermia that have limited their clinical development. Recently, we have discovered a series of brain-penetrant NTR1 modulators, including a lead compound SBI-553, with a unique mechanism of action at NTR1. SBI-553 is an orally available and brain penetrant b-arrestin biased allosteric modulator of NTR1, which shows efficacy in a range of addiction models. The literature contains no documented reports of such molecules among positive or negative allosteric modulators of GPCRs. In addition, the unique profile of SBI-553 appears to circumvent the clinically limiting side effects of hypothermia and hypotension displayed by orthosteric NTR1 ligands. While potentially high risk, the activity of SBI-553 has been validated in vitro and in vivo, and the initial safety profiling indicates no issues that would preclude further development. The goal of the application is to develop SBI-553 as a treatment for opioid use disorders. A 2-year UG3 phase is proposed with the primary objective of determining the suitability of SBI-553 (or a backup compound) entering IND-enabling studies followed by a 2-year UH3 phase with the primary objective of completing a Phase 1 single ascending dose study. During the UG3 phase, the team will complete pharmacokinetic (PK) studies and the preclinical safety profile of SBI-553 in a relevant species; identify a backup compound to SBI-553; and conduct definitive cellular and in vivo pharmacology studies with SBI-553 (and/or potential backup) in models of addiction to inform best clinical indication and clinical endpoints (PK/pharmacodynamic). During the UH3 Phase, the team will ensure completion of GMP Synthesis, Stability Testing and Formulation; GLP Toxicology studies; and the Phase 1 single ascending dose study.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LAWRENCE S. BARAK其他文献

LAWRENCE S. BARAK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LAWRENCE S. BARAK', 18)}}的其他基金

Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders
开发 SBI-553(一种 NTR1 变构调节剂),用于治疗物质使用障碍
  • 批准号:
    10909417
  • 财政年份:
    2019
  • 资助金额:
    $ 358.89万
  • 项目类别:
Beta-arrestin Regulation of Ghrelin Signaling in Modulating Addictive Behavior
β-抑制素对 Ghrelin 信号传导在调节成瘾行为中的调节
  • 批准号:
    8811411
  • 财政年份:
    2014
  • 资助金额:
    $ 358.89万
  • 项目类别:
Beta-arrestin Regulation of Ghrelin Signaling in Modulating Addictive Behavior
β-抑制素对 Ghrelin 信号传导在调节成瘾行为中的调节
  • 批准号:
    8637290
  • 财政年份:
    2014
  • 资助金额:
    $ 358.89万
  • 项目类别:
Science Plan
科学计划
  • 批准号:
    7996726
  • 财政年份:
    2010
  • 资助金额:
    $ 358.89万
  • 项目类别:
Small Molecule Agonsists for the Neurotensin 1 Receptor
神经降压素 1 受体的小分子激动剂
  • 批准号:
    7845378
  • 财政年份:
    2009
  • 资助金额:
    $ 358.89万
  • 项目类别:
Small Molecule Agonsists for the Neurotensin 1 Receptor
神经降压素 1 受体的小分子激动剂
  • 批准号:
    7996532
  • 财政年份:
    2009
  • 资助金额:
    $ 358.89万
  • 项目类别:
Molecular fingerprinting of GPCR ligands in Cancer
癌症中 GPCR 配体的分子指纹图谱
  • 批准号:
    6861075
  • 财政年份:
    2004
  • 资助金额:
    $ 358.89万
  • 项目类别:
Molecular fingerprinting of GPCR ligands in Cancer
癌症中 GPCR 配体的分子指纹图谱
  • 批准号:
    6783797
  • 财政年份:
    2004
  • 资助金额:
    $ 358.89万
  • 项目类别:
MECHANISMS OF G PROTEIN COUPLED RECEPTOR REGULATION
G 蛋白偶联受体调节机制
  • 批准号:
    2906525
  • 财政年份:
    1999
  • 资助金额:
    $ 358.89万
  • 项目类别:
MECHANISMS OF G PROTEIN COUPLED RECEPTOR REGULATION
G 蛋白偶联受体调节机制
  • 批准号:
    6390099
  • 财政年份:
    1999
  • 资助金额:
    $ 358.89万
  • 项目类别:

相似海外基金

Relationship between neurotoxicity and the chemical structures of amphetamines
安非他明的神经毒性与化学结构的关系
  • 批准号:
    25860103
  • 财政年份:
    2013
  • 资助金额:
    $ 358.89万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Search for protein expression in amphetamines treated mouse heart : Challenge to the diagnosis for the sudden death of amphetamines abusers
寻找安非他明治疗小鼠心脏中的蛋白质表达:对安非他明滥用者猝死诊断的挑战
  • 批准号:
    22659138
  • 财政年份:
    2010
  • 资助金额:
    $ 358.89万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
  • 批准号:
    8312648
  • 财政年份:
    2010
  • 资助金额:
    $ 358.89万
  • 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
  • 批准号:
    8531900
  • 财政年份:
    2010
  • 资助金额:
    $ 358.89万
  • 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
  • 批准号:
    8715749
  • 财政年份:
    2010
  • 资助金额:
    $ 358.89万
  • 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
  • 批准号:
    8144930
  • 财政年份:
    2010
  • 资助金额:
    $ 358.89万
  • 项目类别:
Translational Genetics and Dopamine Signaling in Sensitivity to Amphetamines
安非他明敏感性中的转化遗传学和多巴胺信号传导
  • 批准号:
    7675601
  • 财政年份:
    2009
  • 资助金额:
    $ 358.89万
  • 项目类别:
Simultaneous determination of ephedrines, amphetamines, cocaine, cocaine metabolites, and opiates and interaction in the rat
大鼠体内麻黄碱、安非他明、可卡因、可卡因代谢物和阿片类药物的同时测定及其相互作用
  • 批准号:
    17590585
  • 财政年份:
    2005
  • 资助金额:
    $ 358.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study for practical use of two chiral analyses of amphetamines by gas chromatography-mass spectrometry
气相色谱-质谱法对苯丙胺两种手性分析的实用化研究
  • 批准号:
    17590588
  • 财政年份:
    2005
  • 资助金额:
    $ 358.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines
3,4-亚甲二氧基安非他明的临床药理学
  • 批准号:
    6870119
  • 财政年份:
    2004
  • 资助金额:
    $ 358.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了